| 2000 |
STAM2 is tyrosine-phosphorylated downstream of growth factor receptors (EGF, PDGF) and cytokines (IL-3, IL-2); it is phosphorylated by Jak1 and Jak2 (but not the unrelated Tec kinase Etk), requiring the ITAM domain for JAK-mediated phosphorylation; overexpression of wild-type STAM2 potentiates IL-2-mediated c-Myc promoter activation. |
Anti-phosphotyrosine affinity purification + mass spectrometry identification; co-expression with kinase constructs; deletion mutant analysis; reporter assay |
The Journal of biological chemistry |
Medium |
10993906
|
| 2000 |
STAM2 physically associates with Jak2 and Jak3 and is involved in DNA synthesis and c-myc induction signaling downstream of IL-2 and GM-CSF; SH3 domain deletion mutants of STAM1 and STAM2 additively suppress DNA synthesis, indicating compensatory roles. |
Co-immunoprecipitation; SH3 deletion mutants; DNA synthesis assay; c-myc reporter assay |
FEBS letters |
Medium |
10899310
|
| 2002 |
T-cell-specific double knockout of STAM1 and STAM2 causes significant reduction in thymocytes and peripheral T cells with defective TCR-stimulated proliferation; double-mutant thymocytes show prolonged p38 MAPK and JNK activation and increased apoptosis, but proximal IL-2/IL-7 signaling (STAT5, ERK, PKB/Akt) is normal, placing STAMs in a pro-survival pathway downstream of TCR that suppresses apoptosis. |
Conditional double knockout (Cre/loxP); flow cytometry; proliferation assays; western blot for signaling intermediates; cell viability assay |
Molecular and cellular biology |
High |
12446783
|
| 2010 |
PTP1B directly dephosphorylates STAM2 at defined phosphotyrosine sites; knockdown of PTP1B augments STAM2 phosphorylation; phosphorylated STAM2 suppresses Akt activation, and a phosphorylation-deficient STAM2 mutant shows prolonged endosomal localization after EGF stimulation. |
Co-immunoprecipitation; PTP1B knockdown; phosphorylation-deficient mutant; subcellular localization by imaging; Akt activation assay |
The Journal of biological chemistry |
Medium |
20504764
|
| 2010 |
NMR solution structure of the STAM2 VHS domain in complex with monoubiquitin; VHS binds K48-linked diubiquitin in a distinct mode (entering the hydrophobic pocket with differential affinity for each subunit) compared with monoubiquitin or K63-linked diubiquitin (similar binding mode to monoubiquitin), explaining VHS preference for K63 chains. |
Solution NMR; chemical shift perturbations; spin relaxation; paramagnetic relaxation enhancements |
Biochemistry |
High |
21121635
|
| 2012 |
STAM2 VHS-UIM cooperatively binds K63-linked diubiquitin with avidity not seen for monoubiquitin or K48-linked diubiquitin; the distal ubiquitin of K63 chains stabilizes UIM helical structure and the complex adopts a specific structural organization, explaining better sorting efficiency for K63-polyubiquitinated cargo. |
NMR; ITC; binding affinity measurements with VHS-UIM construct and diubiquitin variants |
The Journal of biological chemistry |
High |
22493438
|
| 2012 |
The SH3 domain of STAM2 constitutes a third ubiquitin-binding domain; UBPY-derived peptide and ubiquitin compete for binding to the STAM2 SH3 domain, suggesting the SH3 domain plays dual roles in ubiquitin-mediated receptor sorting and DUB recruitment. |
NMR chemical shift perturbation; competitive binding assays |
FEBS letters |
Medium |
22841719
|
| 2015 |
STAM2 localizes to early endosomes in neurons; uniquely, STAM2 also localizes to the nucleus in neurons, distinct from other ESCRT-0 members (Hrs) which co-localize with STAM2 only in the cytoplasm. |
Subcellular fractionation; co-immunofluorescence confocal microscopy; lacZ reporter gene trap mouse line |
Molecular and cellular neurosciences |
Medium |
26101075
|
| 2016 |
Crystal structure of the HD-PTP Bro1 domain in complex with the STAM2 core region shows STAM2 binds the hydrophobic concave pocket of HD-PTP Bro1 in the opposite orientation to CHMP4B; Thr145 of HD-PTP is the key determinant distinguishing HD-PTP from Alix/Brox, as Alix- or Brox-mimicking mutations of this residue abolish STAM2 binding. |
X-ray crystal structure; mutagenesis; binding assays |
PloS one |
High |
26866605
|
| 2016 |
The AMSH SH3 binding motif (AMSH-SBM) outcompetes Lys63-linked diubiquitin for binding to the STAM2 SH3 domain; NMR structure of AMSH-SBM/SH3 complex reveals structural organization where AMSH-SBM correctly positions AMSH for polyubiquitin chain cleavage, explaining how STAM2 stimulates AMSH deubiquitinase activity. |
NMR; solution NMR structure; competitive binding assays with kinetic analysis |
Journal of molecular biology |
High |
27725184
|
| 2019 |
Linker length and flexibility between the UIM and SH3 domains of STAM2 modulates recognition of Lys63-linked diubiquitin; shortening or lengthening the linker reduces affinity for Lys63-Ub2 up to ~8-fold, indicating interdomain dynamics tune binding. |
SAXS; NMR; engineered linker variants with affinity measurements |
Scientific reports |
Medium |
31601934
|
| 2021 |
STAM2 knockdown in gastric cancer cells inhibits proliferation, cell cycle progression, migration, and invasion, and decreases phosphorylation of JAK2 and STAT3 as well as expression of MMP2 and MMP9, placing STAM2 upstream of the JAK2/STAT3 signaling axis. |
siRNA knockdown; CCK-8, EdU, flow cytometry, wound-healing, Boyden chamber assays; western blot; rescue assays |
Acta biochimica et biophysica Sinica |
Medium |
33778841
|
| 2025 |
STAM2 (not STAM1) directly binds cell-surface PD-L1 via its VHS domain and binds HRS via its ITAM domain, acting as a molecular bridge to initiate biogenesis of PD-L1+ small extracellular vesicles in oral squamous cell carcinoma. |
Co-immunoprecipitation; domain deletion/mutant analysis; sEV isolation and characterization |
International journal of biological macromolecules |
Medium |
40541896
|
| 2025 |
O-GlcNAcylation of STAM2 at serine 375 (driven by GFAT1 upregulation) stabilizes STAM2 protein by inhibiting proteasomal degradation and ubiquitination; O-GlcNAcylated STAM2 promotes JAK2 and STAT3 phosphorylation to activate epithelial-mesenchymal transition in bladder cancer. |
GFAT1 inhibition; OGT inhibitor; mass spectrometry identification of modification site; proteasome assay; western blot for STAT3/JAK2 phosphorylation; metastasis assays |
Scientific reports |
Medium |
40075080
|